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Abstract
Background: The objective of this study was to perform simulated-use testing as well as a clinical study to assess the 
efficacy of the EVOTECH® Endoscope Cleaner and Reprocessor (ECR) cleaning for flexible colonoscopes, 
duodenoscopes, gastroscopes and bronchoscopes. The main aim was to determine if the cleaning achieved using the 
ECR was at least equivalent to that achieved using optimal manual cleaning.
Methods: Simulated-use testing consisted of inoculating all scope channels and two surface sites with Artificial Test 
Soil (ATS) containing 108 cfu/mL of Enterococcus faecalis, Pseudomonas aeruginosa and Candida albicans. 
Duodenoscopes, colonoscopes, and bronchoscopes (all Olympus endoscopes) were included in the simulated use 
testing. Each endoscope type was tested in triplicate and all channels and two surface sites were sampled for each 
scope. The clinical study evaluated patient-used duodenoscopes, bronchoscopes, colonoscopes, and gastroscopes 
(scopes used for emergency procedures were excluded) that had only a bedside flush prior to being processed in the 
ECR (i.e. no manual cleaning). There were 10 to 15 endoscopes evaluated post-cleaning and to ensure the entire ECR 
cycle was effective, 5 endoscopes were evaluated post-cleaning and post-high level disinfection. All channels and two 
external surface locations were sampled to evaluate the residual organic and microbial load. Effective cleaning of 
endoscope surfaces and channels was deemed to have been achieved if there was < 6.4 μg/cm2 of residual protein, < 
1.8 μg/cm2 of residual hemoglobin and < 4 Log10 viable bacteria/cm2. Published data indicate that routine manual 
cleaning can achieve these endpoints so the ECR cleaning efficacy must meet or exceed these to establish that the ECR 
cleaning cycle could replace manual cleaning
Results: In the clinical study 75 patient-used scopes were evaluated post cleaning and 98.8% of surfaces and 99.7% of 
lumens met or surpassed the cleaning endpoints set for protein, hemoglobin and bioburden residuals. In the 
simulated-use study 100% of the Olympus colonoscopes, duodenoscopes and bronchoscopes evaluated met or 
surpassed the cleaning endpoints set for protein, and bioburden residuals (hemoglobin was not evaluated).
Conclusions: The ECR cleaning cycle provides an effective automated approach that ensures surfaces and channels of 
flexible endoscopes are adequately cleaned after having only a bedside flush but no manual cleaning. It is crucial to 
note that endoscopes used for emergency procedures or where reprocessing is delayed for more than one hour MUST 
still be manually cleaned prior to placing them in the ECR.
Background
Cleaning and disinfection of flexible endoscopes presents
a significant challenge to reprocessing personnel because
of the pressure to quickly turn around the patient-used
endoscope so that it is ready for the next patient. In addi-
tion to pressure on staff to rush the process there is also
the challenge of how well trained and competent the
reprocessing personnel are. Current guidelines [1-3] rec-
ommend that specific and thorough training be provided
initially as well as on an ongoing basis as technology is
rapidly changing and adequate training of reprocessing
staff on newly acquired models is often overlooked. The
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manual cleaning phase is a critical part of the reprocess-
ing protocol and is prone to errors [1-11]. These human
errors may include; failing to clean channels because staff
were not aware of them, failing to properly assess if chan-
nels are blocked or leaking, or not flushing adequate fluid
volumes through all channels. Puszko [12] demonstrated
that manual flushing of channels during the cleaning
phase results in potential for repetitive strain injuries in
reprocessing personnel and that using flushing pumps
provided a more reliable way to ensure adequate fluid
volumes were consistently used. The greatest concern
when errors are made is that high-level-disinfection
(HLD) may be inadequate thereby allowing infectious
organisms to survive and be transmitted to the next
patient that the endoscope is used on. Infection transmis-
sion and chemical colitis associated with improper repro-
cessing of flexible endoscopes still is a concern [5,13-17].
Despite the advent of automated endoscope reprocessors
that have "wash cycles" as part of the whole process, there
are a number of studies that question the cleaning effi-
cacy of such cycles [18-21]. Recent simulated-use evalua-
tion of the washing provided by the Reliance Endoscope
Processing System indicated that it provided cleaning
that was equivalent to manual cleaning [22] but that clini-
cal testing was needed.
The EVOTECH® Endoscope Cleaner and Reprocessor
(ECR) has received FDA clearance for cleaning claims
that eliminate the need for manual cleaning prior to High
Level Disinfection (HLD). Despite this, the Society of
Gastrointestinal Nurses and Associates (SGNA) has
alerted users in 2007 and again in 2009 that manual
cleaning should be continued until clinical testing data is
available to confirm that the ECR can provide reliable
cleaning without the full manual cleaning process [23,24].
The primary objective of this study was to use simu-
lated-use testing as well as a clinical study to evaluate the
efficacy of the ECR in removing bioburden and organic
material from the channels and surfaces of flexible endo-
scopes.
Methods
EVOTECH® Endoscope Cleaner and Reprocessor (Hereafter 
referred to as the ECR)
The ECR (Advanced Sterilization Products, Irvine, CA)
was located in the endoscopy clinic of a large tertiary care
hospital. The ECR consists of two independently oper-
ated endoscope reprocessing basins controlled by a single
processor, with sub-systems that monitor and control
temperature, pressure, fluid flow rate and the water,
detergent, disinfectant and alcohol delivery systems. The
ECR was fed with softened tap water as per the manufac-
turer's instructions. As per the manufacturer's instruc-
tions the valves were manually cleared prior to placing in
the ECR. A unique software program was made available
in the ECR that allowed the cycle to be stopped at the end
of the cleaning phase such that samples could be col-
lected from the processed endoscopes prior to HLD
(Note; this cycle is not commercially available)
CIDEZYME®-GI Detergent (Advanced Sterilization Prod-
ucts Irvine, CA) was the enzymatic detergent used in the
ECR cleaning cycle at 1:185 dilution (as per manufac-
turer's recommended use-dilution). As indicated in the
ECR manufacturer's cycle parameters, once the repro-
cessing cycle has been initiated, the first step is the leak
test. If the pressure does not reach the target and stabilize
or if a substantial leak is detected, the cycle cancels. The
next step is a pre-rinse where the basin is filled with
ambient temperature filtered water (all filtered water in
the cycle is achieved using 0.2 μm filtration) to remove
any gross contamination in the channels. The water is
pumped through the endoscope channels and drained.
The pre-rinse consists of cool water followed by a warm
water rinse. This is followed by the wash stage where the
basin is filled with filtered water to which CIDEZYME®-
GI detergent is added. The water temperature during the
entire cleaning phase is held at 35°C (if the water temper-
ature falls below this the cycle will be aborted and an
error message displayed). The detergent solution is circu-
lated for 3 minutes and then drained and followed by a
rinse. Filtered air is blown through the channels. An auto-
mated blockage test in then performed on each individual
channel with specific criteria for each channel to deter-
mine pass or fail. After the blockage test the rinse stage
begins during which the basin is filled with filtered water
at 45°C and circulated through the channels for at least 30
seconds then drained. The ECR then disinfects the endo-
scope by perfusing all lumens with a 0.055% in-use con-
centration of CIDEX® OPA concentrate solution that is
held at 50-55°C and circulated through the channels for 5
minutes. At the end of the HLD cycle the disinfectant
solution is drained and filtered air is blown through the
channels. After HLD, two rinses are performed using fil-
tered water. After the final rinse, filtered air is blown
through the channels. Following the cleaning and HLD
cycle, there is an optional flush with 70% isopropyl alco-
hol. Finally the leak test is repeated.
The entire cleaning phase (includes rinses and deter-
gent exposure phase) is approximately 10 to12 minutes
long. CIDEZYME®-GI detergent is the only one recom-
mended by the ECR manufacturer and the results
obtained in this study apply to the ECR only when this
detergent is used.
Cleaning Study overview
The study was carried out in two phases with Phase I
being a clinical in-use study and Phase II being a simu-
lated-use study. These two phases were necessary to
ensure that the ECR cleaning cycle was thoroughly evalu-Alfa et al. BMC Infectious Diseases 2010, 10:200
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ated under actual patient-use conditions (where soiling
levels were reflective of what happens in actual usage but
where the level of soiling cannot be controlled, i.e. worst-
case clinical conditions) as well as under controlled inoc-
ulation studies where all channels and surface test sites
could be reproducibly inoculated with high bioburden
and organic levels (i.e. worst-case simulated-use condi-
tions that are representative of worst-case clinical condi-
tions).
The accepted benchmark(s) for adequate cleaning are
still under debate and the only currently published
benchmarks for residual organic and bioburden levels in
flexible endoscopes that are based on clinical measure-
ments are those referred to in the AAMI ST35 [8] and
TIR30 [25] which are based on the work published by
Alfa et al [26,27]. These published benchmarks were used
in this current study to assess the adequacy of cleaning
for both Phase I and II studies and were set at; < 6.4 ug/
cm2 of residual protein, < 1.8 ug/cm2 of hemoglobin and <
4 log10 viable bacteria/cm2 [25,28]. As such those samples
collected from the endoscope channel or surface after
ECR cleaning in the current study that had organic and
bioburden levels lower than the stated benchmarks were
considered to have been adequately cleaned (i.e. equiva-
lent to routine manual cleaning). Previously reported
testing has shown that manual cleaning of endoscopes
tested after routine cleaning of patient-used endoscopes
[27] as well as those tested after inoculation using ATS in
simulated-use studies do achieve these benchmarks [26].
The step by step manual cleaning protocol that was used
for comparison to the ECR cleaning cycle took experi-
enced research personnel between 14 minutes (broncho-
scopes) to 25 minutes (side-viewing duodenoscope) to
complete. The 14 step manual cleaning process (no flush-
ing pumps used in this protocol) is clearly described in
Alfa et al [26].
Microbial cultures
The bacterial strains used for Phase II simulated-use test-
ing included; Enterococcus faecalis (EF) ATCC 29212,
Pseudomonas aeruginosa (PA) ATCC 27853, and Can-
dida albicans (CA) ATCC 14053. All microorganisms
were stored as frozen skim milk stocks at -70°C and were
passaged three times before use in any testing. All micro-
organisms were grown on Tryptone Soya Agar + 5%
Sheep Blood (BA) (Oxoid Inc. cat #MP2012).
Organic Test Soil
The organic challenge was provided using Artificial Test
soil-thickened (ATS-T; US Patent # 6,447,990; inventor
Dr. Michelle Alfa) which was prepared fresh, stored at
4°C and used within one month of preparation as
described by Alfa et al [26,22]. This test soil was formu-
lated to reflect the worst-case levels of organic material
based on data obtained from patient-used flexible endo-
scopes [26], Patent # 6,447,990] prior to bedside pre-
cleaning or manual cleaning. The three test organisms
were added to achieve a final concentration of approxi-
mately 108 cfu/mL in ATS-T. The main components in
ATS-T include; whole sheep blood, serum, physiological
solution and a thickening agent. The protein, carbohy-
drate, haemoglobin and bioburden levels in ATS-T were
representative of the worst-case levels found in patient-
used flexible endoscopes [22].
Effect of CIDEZYME®-GI detergent on viability of test 
microorganisms
CIDEZYME®-GI was prepared at its use-dilution (1:185
dilution) using sterile tap water as well as sterile tap water
controls were held in a heating block at 35°C. Test organ-
isms were added to achieve a final concentration of
approximately 106  cfu/mL of each organism. Samples
were collected after 1, 3, 5 and 10 minutes exposure and
viable counts performed using the spread-plate tech-
nique. Testing over the 10 minutes timeframe was
selected because the length of exposure to enzymatic
detergent in the ECR is approximately 3 minutes.
Phase I Clinical Use study
The clinical use (CU) study consisted of patient-used
flexible endoscopes used for a variety of non-emergency
procedures. Normally flexible endoscopes used on
patients receive "bedside pre-cleaning" and then are
transported to the reprocessing area where they are leak
tested and then have "manual cleaning" followed by HLD.
Bedside pre-cleaning consisted of flushing enzymatic
detergent solution (Renuzyme used at 1:32 use-dilution)
through all channels and wiping off the exterior of the
insertion tube using a cloth moistened with the same
enzymatic detergent. The manual cleaning consisted of
immersing the scope in use-dilution enzymatic detergent
(Renuzyme used at 1:64 use-dilution), brushing of the
suction-biopsy channel (and any other channel that the
endoscope manufacturer recommended brushing), flush-
ing all channels with enzymatic detergent while
immersed followed by transfer and immersion in a basin
of tap water and flushing all channels while immersed.
The ECR manufacturer states that flexible endoscopes
used for emergency procedures or that have transit times
beyond one hour require full manual cleaning prior to
placement in the ECR. For this study flexible endoscopes
used for emergency procedures were excluded and all
patient-used endoscopes evaluated had transit times of
less than one hour. The patient-used endoscopes evalu-
ated in this study were given the usual bedside pre-clean-
ing with enzymatic detergent solution and then placed
directly into the ECR. The CU study involved 15 bron-
choscopes where 10 received cleaning only, 5 receivedAlfa et al. BMC Infectious Diseases 2010, 10:200
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cleaning and high level disinfection (HLD). In addition
there were 20 colonoscopes, 20 duodenoscopes and 20
gastroscopes with 15 of each scope type receiving clean-
ing only and an additional 5 that received cleaning and
HLD (Table 1). Both FDA guidance documents [28] and
AAMI [25] recommend that testing be performed to
assess each phase of the washer-disinfector cycle as well
as the entire process. Therefore, this approach was used
for the current study and samples were collected to evalu-
ate the cleaning phase as well as the entire cleaning and
HLD cycle of the ECR.
The flexible video endoscopes evaluated in this study
were all Olympus scopes including; bronchscope models
BF-P60 and BF-P40, duodenoscope model TJF-160VF,
colonoscope models CF-Q180AL and CF-H180AL and
gastroscope models GIF-Q180 and GIF-H180 (more
details of the dimensions of these specific models of
endoscopes can be found on the manufacturer's website).
Since the internal surface area of flexible endoscopes is
not provided by the endoscope manufacturers, the chan-
nel length was measured by threading fishing wire
through the channel and this measurement along with
the channel inner diameter (which is provided by the
scope manufacturers) was used to calculate the surface
area for each channel.
The patient-used endoscopes that were processed
through the ECR were then fully reprocessed using the
routine process of manual cleaning followed by HLD.
This additional reprocessing was required by the site as
this was considered to be a research study. Research and
Ethics approval was obtained and since each scope was
double-processed (i.e. research sample collected and then
reprocessed by usual endoscopy clinic protocol)
informed consent from the patients was not required.
Phase II Simulated-use Study
The simulated-use (SU) study was performed using all
Olympus scopes including; bronchoscope BF P40, duo-
denoscope JF 1T30 and colonoscope CF 40L. Table 1 out-
lines the channels and surface sites tested (more details of
the dimensions of these specific models of endoscopes
can be found on the manufacturer's website). The inner
surface area of the channels was calculated as described
for the clinical endoscopes. These scopes were only used
for research purposes and were not used on any patients.
Every channel in the scope being studied was perfused
completely with ATS containing 108 cfu/mL of each test
organism as described in Alfa et al [26] Once the channel
was perfused, excess inoculum was flushed out using air.
Two surface sites (1 cm2 surface area) were then inocu-
lated with 50 μL of ATS-microbe mixture that was spread
over a 1cm2 surface area. A template was used to indicate
the surface area to inoculate. The inoculated endoscope
was allowed to dry for one hour. Negative controls (unin-
oculated endoscopes) and positive controls (inoculated
endoscopes that did not receive any cleaning) were
included in the study. This inoculation process has been
utilized in the authors research lab since 1999 [26].
Endoscope sample collection
All channels from SU and CU endoscopes were evaluated
by collecting samples using the "flush only" method or the
"flush-brush-flush" method described by Alfa et al [22].
The total sample volume was 40 mLs for L1, 20 mLs for
L2, 10 mLs for L3 and 5 mLs for L4. The surface sites
were sampled as described by Alfa et al [22] by using a
pre-moistened swab that was rubbed vigorously over the
inoculated 1 cm2 surface area (a template was used to
indicate the surface area to sample) and then placed into
2 mLs of sterile reverse osmosis (RO) water. The samples
from lumens and surfaces were mixed for 1 min on a vor-
tex mixer, sonicated (Bransonic 1200 ultrasonic bath,
Bransonic Canada, Pickering, ON) for three 5 second
pulses, and then mixed a second time for 1 min on a vor-
tex mixer. The sampling method was validated using
repeated rounds of sample collection to demonstrate that
≥ 95% of the organic and bioburden residuals were recov-
ered in the first round of sample collection and that there
was no added value in more extensive sampling. These
data are not shown as the testing was done prior to this
study and this sampling method has been in use since
then.
Quantitative assays for endoscope samples
The endoscope samples collected were each assayed to
determine the protein, and hemoglobin concentrations as
well as the bioburden level. The QunatiPro BCA Assay kit
which includes a bovine serum albumin protein standard
and uses bicinchoninic acid (Sigma, St. Louis, Missouri)
was used for protein quantitation. The TMB (3,3',5,5'
Tetramethylbenzadine) Liquid substrate system for
ELISA (Sigma) was used in conjunction with a 80 mg/dL
cyanonethemoglobin standard (Stanbio Laboratory,
Boerne, texas) for haemoglobin quantitation. Both the
protein and haemoglobin assay were used as per the man-
ufacturer's instructions. The limit of detection (LD) for
the protein assay was 0.5 μg/mL and for the haemoglobin
assay the LD was 5 μg/mL. These samples were also
assayed to determine the level of bioburden using stan-
dard spread plate technique. Briefly, viable counts using
serial 1:10 dilutions with triplicate spread plates inocu-
lated with 0.1 mLs were performed using BBL™
CHROMagar™ Orientation media as this facilitated dif-
ferentiating the three different types of microorganisms
as they produced different colored colonies in this media.
The limit of detection for the viable count assay was 10
cfu/mL. For more detailed description of the methods
used please see Alfa et al [26].Alfa et al. BMC Infectious Diseases 2010, 10:200
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Table 1: Summary of scopes and samples tested for Clinical-use and Simulated-use evaluations
Site Colonoscope Gastroscope Bronchoscope Duodenoscope
(N = 20)** (N = 20)** (N = 15)** (N = 20)**
Clinical-use Testing:
Surface
S1 (insertion tube*) √ √ √ √
S2 (control head*) √ √ √ √
L1: Suction biopsy channel (umbilical to distal end) √ √ √ √
[364.5 cm2]1 [255.7 cm2] [53.2 (or 58.7) cm2] [402 cm2]
L2: Air/water channel (umbilical to distal end) √ √ √
[377 cm2] [ 269 (or 254) cm2] [363 cm2]
L3: Auxiliary water channel √
[175.3 cm2]
L4 Elevator wire channel √
[43.4 cm2]
Samples collected per endoscope 5 4 3 5
Simulated-use Testing; each scope type tested in triplicate***
Site Colonoscope Gastroscope Bronchoscope Duodenoscope
(N = 3) Not done (N = 3) (N = 3)
Surface
S1 (insertion tube)**** √ √ √
S2 (control head)**** √ √ √
L1: Suction biopsy channel (From umbilical to distal end) √ √ √
[358.7 cm2] [53.2 cm2] [307.5 cm2]
L2: Air/water channel (From umbilical to distal end) √ √
[345 cm2] [213.9 cm2]
L4 Elevator wire channel √
[34 cm2]
Samples per scope 4 3 5
* Surface area sampled was 1 cm2 for each site
** Clinical use testing: Colonoscope, Gastroscope and Duodenoscope: 15 tested after cleaning only, 5 tested after cleaning and HLD, 
Bronchoscope: 10 tested after cleaning only, 5 tested after cleaning and HLD
*** Simulated use testing: Colonoscope, Bronchoscope and Duodenoscope: positive and negative controls as well as ECR cleaning was tested for 
each scope type in triplicate.
**** Surface area inoculated and sampled was 1 cm2 for each site
1 The calculated surface area was determined using the manufacturer's published lumen diameter and the length of the channel as determined 
by threading a fishing wire down the channel lumen and measuring the length. Where two values are stated these refer to the two different scope 
models used for this study.Alfa et al. BMC Infectious Diseases 2010, 10:200
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Reprocessing of simulated-use endoscopes
After sample collection was completed all endoscopes
were leak tested (Olympus Model MU-1 leak tester) and
if no leaks detected they were then fully manually cleaned
(following the manufacturer's instructions). A suction
Pump (Olympus model SSU-2) and flushing pump (PCI
Medical Model EFP-250) were used for this manual
cleaning process as per the manufacturer's instructions.
Once fully cleaned the research endoscopes were pro-
cessed through the ASP Automated Endoscope Repro-
cessor (AER) for HLD using CIDEX®OPA Solution.
Data analysis
As has been done in previously published analysis of AER
cleaning [22] efficacy negative controls (baseline) con-
sisted of samples taken from the flexible endoscopes that
had been cleaned and high level disinfected (i.e. patient
ready endoscopes in the Clinical study and non-soiled
endoscopes in the Simulated-use study). All data pre-
sented in the tables and figures has been normalized
against the corresponding baseline samples (i.e. the aver-
age value obtained for clean, disinfected endoscopes was
subtracted from the each test value). This is represented
by the following equation:
Where:
[XPN] represents the "normalized" amount of residual
protein, haemoglobin or bioburden/cm2 for the patient-
used scope tested.
XP represents the amount of residual protein, haemo-
globin or bioburdern/cm2 after the patient-used endo-
scope had been cleaned or cleaned and HLD.
BP represents the average amount of residual protein,
haemoglobin or bioburden/cm2 for five fully reprocessed
endoscopes that were patient-ready but had not yet been
used.
The same calculations described for normalization
were done for the samples collected during the Phase II
Simulated-use study.
This approach was used to account for any low levels of
organic residuals that may be present due to routine han-
dling as flexible endoscopes are not stored under sterile
conditions. In addition this approach helps confirm that
there was no "accumulation" of material over the duration
of the study.
Results
Since viable counts were one of the benchmarks being
assessed, it is necessary to ensure that the exposure to
detergent alone did not contribute significantly to the
killing of the test microorganisms. Figure 1 shows the
results of this testing. P. aeruginosa was the only microor-
ganism affected by exposure to the enzymatic detergent
and the net effect was a 1.0 Log10 reduction in viability
after 3 minutes exposure (length of detergent exposure in
ECR). The viability of the other two test organisms was
not affected even after 10 minutes of detergent exposure
at 35°C.
The clinical-use evaluation was carried out over an
eight month period. Bronchoscopes, colonoscopes, duo-
denoscopes and gastroscopes were evaluated after ECR
cleaning only as well as after a full cycle that included
HLD using CIDEX®  OPA Concentrate in-use (OPAC)
Solution. The range of negative control values confirmed
that there were no abnormally high levels or protein, hae-
moglobin or bioburden in any of the patient-ready endo-
scopes tested. The highest average level detected for
negative controls was 9.248 μg/cm2 protein for the S1
(surface) of bronchoscopes, and 0.346 Log10cfu/cm2 for
bioburden in the L4 channels of duodenoscopes. The
haemoglobin level in all negative scopes for all sites was <
LD. The protein detected most likely would reflect han-
dling and storage under non-sterile conditions as these
protein levels were only detected on surfaces (lumen lev-
els for negative controls for all scope types were all < 6.4
μg/cm2 protein). There were only two surface sites (both
S2) from ECR cleaned patient-used endoscopes that were
> 6.4 μg/cm2 protein before subtracting the average nega-
tive control (these were 8.990 and 6.962 μg/cm2 protein).
The ECR cleaning actually removed some of the pre-
existing residual surface protein remaining from routine
manual cleaning for bronchoscopes at this facility as 5 of
10 negative controls (i.e. 50% of patient-ready broncho-
scopes not cleaned by ECR (i.e. received regular manual
cleaning) had > 6.4 μg/cm2 protein residuals). The sum-
mary of results after the cleaning phase are shown in
Table 2 (all data has been normalized against the negative
control values as outlined in the Materials and Methods
section). There were five replicates of each scope type
that were fully processed (ECR cleaning and HLD) after
patient use (results not shown in Table 2). Of the 20
endoscopes given full reprocessing there were only two
that showed any residuals above the LD. The L1 channel
only from one of the five colonoscopes and the L1 chan-
nel only from one of the five bronchoscopes had residual
bioburden of 0.35 Log10cfu/cm2 and 0.30 Log10cfu/cm2,
respectively. All other surfaces and lumens from all fully
reprocessed scopes evaluated showed less than the limit
of detection for hemoglobin, protein and bioburden.
To demonstrate how many were totally compliant with
the cleaning benchmarks, Table 3 provides a summary of
all the patient-used scopes and all the sites tested that
were cleaned only by the ECR. The overall compliance of
XPN [] =− XP BPAlfa et al. BMC Infectious Diseases 2010, 10:200
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the ECR cleaning with all benchmarks for surfaces and
lumens was > 99%.
The range of negative control values confirmed that
there were no abnormally high levels or protein, haemo-
globin or bioburden in any of the simulated-use endo-
scopes tested. The highest average level detected for
negative controls was 4.767 μg/cm2 protein for the S1
(surface) of duodenoscopes, and 0.342 Log10cfu/cm2 for
bioburden in the S1 sites of duodenoscopes. These data
confirmed that despite the extensive soiling used for all
channels in this Phase II study that there was no detect-
able "accumulation" of organic material or bioburden
within the channels over the course of the study. Table 4
provides a summary of the simulated-use evaluation
using bronchoscopes, colonoscopes and duodenoscopes
(all values have been normalized against the negative
controls as described in the Materials and Methods Sec-
tion). Simulated-use testing provides reproducible inocu-
lation of all channels as well as the surface sites to be
tested. Unlike clinical-use testing it is possible to have
positive controls and to determine the percentage reduc-
tion for protein residuals as well as the Log10 Reduction
Factor (RF) for bioburden. The overall protein reduction
achieved by the ECR cleaning was > 99% and the overall
bioburden RF was > 4.
Figure 2 provides a summary of the removal of biobur-
den stratified by organism tested. Although the impact of
the detergent may partly explain why P. aeruginosa was
the most susceptible to removal, the data for the other
two test organisms demonstrated that there was signifi-
cant removal of microorganisms from both lumens and
surfaces as neither E. faecalis or C. albicans were affected
by the detergent yet they were effectively removed by the
ECR cleaning (4 to 7 Log10 reduction in bioburden).
Discussion
When the Endoscope Cleaner and Reprocessor (ECR)
was cleared by the United States Food and Drug Admin-
stration (FDA) and first marketed, it was the first com-
mercially available endoscope cleaner and reprocessor
that had label claims regarding the efficacy of the auto-
mated cleaning cycle that allowed elimination of manual
cleaning. Despite the desire for automated cleaning of
patient-used flexible endoscopes, there was concern that
there were no published clinical-use studies for the ECR.
The American Society for Gastrointestinal Endoscopy
(ASGE) and Society of Gastroenterology Nurses and
Figure 1 Effect of CIDEZYME®-GI detergent on viability of E.faecalis, P.aeruginosa and C. albicans. The organisms were suspended in the use-
dilution of the detergent of in tap water controls and at the timed intervals noted samples were taken to determine the level of viable bacteria.
Cidezyme-GI Killing Effect
0
1
2
3
4
5
6
7
Time 0 3 minute 5 minute 10 minute
Exposure Time
L
o
g
1
0
 
c
f
u
/
m
L
E.faecalis Tap water control P.aeruginosa Tap water control C.albicans Tap water control
E.faecalis Cidezyme-GI P.aeruginosa Cidezyme-GI C.albicans Cidezyme-GIAlfa et al. BMC Infectious Diseases 2010, 10:200
http://www.biomedcentral.com/1471-2334/10/200
Page 8 of 14
Table 2: Summary Clinical Use Evaluation
Scope Site: Average of residuals remaining post-cleaning*Average (Standard Deviation) [Range]
Protein μg/cm2 Hemoglobin μg/cm2 Bioburden Log10 cfu/cm2
Bronchoscopes: [N = 10]
S1 < LD < LD < LD
S2 0.32 (0.83) < LD 0.12 (0.26)
[0 - 2.62] [0 - 0.67]
L1 < LD < LD 0.03 (0.09)
[0-0.29]
Colonoscopes: [N = 15]
S1 0.26 (0.79) < LD 0.12 (0.20)
[0-2.94] [0 - 0.67]
S2 1.04 (2.47) < LD 0.02 (0.08)
[0-9.41] [0-0.33]
L1 0.12 (0.12) < LD 0.04 (0.07)
[0-0.32] [0-0.25]
L2 < LD < LD 0.0007 (0.022)
[0-0.008]
L3 < LD < LD 0.007 (0.023)
[0-0.09]
Duodenoscopes: [N = 15]
S1 0.03 (0.11) < LD 0.37 (0.94)
[0-0.44] [0-3.34]
S2 1.28 (3.80) < LD 0.14 (0.53)
[0-14. [0-2.04]
L1 0.21 (0.67) < LD 0.26 (0.97)
[0-2.60] [0-3.78]
L2 0.043 (0.09) < LD 0.11 (0.41)
[0-0.33] [0-1.58]
L4 0.06 (0.11) < LD 0.81 (1.35)
[0-0.31] [0-4.47]Alfa et al. BMC Infectious Diseases 2010, 10:200
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Page 9 of 14
Associates (SGNA) [24] sent out an alert in 2007 to users
regarding the ECR that stated: "Members are cautioned
about dispensing with manual washing and brushing
steps before the capabilities of the new machine are
confirmed in independent studies and in clinical prac-
tice. Lastly, all currently used machines in the United
States are labelled specifically for use only after man-
ual washing with mechanical brushing. Diligence in
application of all steps of washing and disinfection
remains paramount in the safe delivery of endoscopic
services."
There was major concern regarding whether the bed-
side flush combined with the cleaning in the ECR was
sufficient to provide adequate cleaning. The SGNA alert
Gastroscopes: [N = 15]
S1 1.14 (1.77) < LD 0.10 (0.30)
[0-6.44] [0-1.13]
S2 0.63(1.80) < LD 0.03 (0.06)
[0-6.99] [0-0.15]
L1 0.07 (0.20) < LD 0.04 (0.06)
[0-0.75] [0-0.24]
L2 0.03 (0.10) < LD 0.11 (0.35)
[0-0.38] [0-1.22]
* All values have been "normalized" against the baseline (negative) controls (i.e. the average for the negative controls was subtracted for all 
test values). The term "LD" indicates the sample concentration was below the limit of detection. The LD for the protein assay was 0.5 μg/mL, 
for the haemoglobin assay the LD was 5 μg/mL, and for bioburden assay the LD was 10 cfu/mL.
Table 2: Summary Clinical Use Evaluation (Continued)
Table 3: Summary of Patient-used endoscopes; compliance with cleaning benchmarks after ECR cleaning cycle
Number of sites compliant with cleaning benchmark (All scope types combined)*
Hemoglobin Protein Bioburden
(< 1.8 μg/cm2) (< 6.4 μg/cm2) (< 4 Log10/cm2)
S1 53/53 (100%) 52/53 (98%) 55/55 (100%)
S2 55/55 (100%) 52/55 (95%) 55/55 (100%)
All Surfaces, All benchmarks: 322/326 (98.8%)
L1 54/54 (100%) 54/54 (100%) 54/54 (100%)
L2 45/45 (100%) 45/45 (100%) 45/45 (100%)
L3 15/15 (100%) 15/15 (100%) 15/15 (100%)
L4 15/15 (100%) 15/15 (100%) 14/15 (93%)
All Lumens, All benchmarks: 386/387 (99.7%)
* Note: there were two S1 samples that were not collected from one colonoscope and from one duodenoscope and one L1 sample that were 
accidentally lost during processing and was not available for analysis so the demoninator value is 53 or 54 instead of 55.Alfa et al. BMC Infectious Diseases 2010, 10:200
http://www.biomedcentral.com/1471-2334/10/200
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Table 4: Summary Simulated-use evaluation
Average of residuals:*
Scope Site: Protein μg/cm2 Bioburden Log10/cm2**
Average (STD) Average (STD)
Pos control Post-clean % Reduction Pos control Post-clean RF***
Bronchoscopes: [N = 3]
S1 1229.6 (133.9) 4.8 (1.5) 99.6% 7.08 (0.23) < LD ≥ 7.08
S2 887.6 (388.6) 2.5 (2.2) 99.7% 7.01 (0.21) < LD ≥ 7.01
L1 517.6 (221.3) 1.4 (1.7) 99.7% 6.71 (0.45) 1.19 (1.10) 5.52
Colonoscopes: [N = 3]
S1 1663.6 (246.2) 1.13 (2.4) 99.9% 6.35 (0.37) < LD ≥ 6.35
S2 1677.9 (178.3) 2.01 (0.92) 99.9% 6.99 (0.25) 0.31 (0.25) 6.69
L1 437.4 (118.4) 0.23 (0.14) 99.9% 6.54 (0.21) 0.61 (0.69) 5.93
L2 458.2 (111.1) 0.17 (0.11) 99.9% 6.46 (0.31) 1.56 (1.14) 4.90
Duodenoscopes: [N = 3]
S1 1703.3 (231.8) < LD ≥ 99.99% 5.95 (0.45) 0.05 (0.08) 5.90
S2 1287.9 (115.5) < LD ≥ 99.99% 6.52 (0.19) 0.01 (0.02) 6.51
L1 378.0 (89.6) 0.02 (0.10) > 99.99% 6.44 (0.19) 0.09 (0.16) 6.35
L2 368.9 (71.5) 0.02 (0.04) > 99.99% 6.59 (0.07) 1.05 (1.24) 5.54
L4 136.1 (17.6) < LD ≥ 99.99% 5.88 (0.65) 1.87 (0.65) 4.01
* Note: The residuals for protein and bioburden for all sites tested met the benchmark for cleaning of < 6.4 ug/cm2 protein and < 4 Log10 cfu/
cm2 bioburden. Each value represents the average of triplicate tests. All values have been "normalized" against the baseline (negative) 
controls (i.e. the average for the negative controls was subtracted for all test values). The term "LD" indicates that the sample concentration 
was below the limit of detection. The LD for the protein assay was 0.5 μg/mL and for the bioburden assay the LD was 10 cfu/mL.
**Average of all three microorganisms together
*** RF; Log10 Reduction factorAlfa et al. BMC Infectious Diseases 2010, 10:200
http://www.biomedcentral.com/1471-2334/10/200
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Figure 2 A summary of the simulated-use testing to assess the reduction in E. faecalis, P. aeruginosa and C. albicans after ECR cleaning. All 
results represent the average and standard deviation for three replicate experiments. S1 and S2 represent samples from 1 cm2 surface sites on the 
insertion tube and control head, respectively. L1, L2, L4 represent samples taken from the suction-biopsy, air-water and elevator guidewire channels, 
respectively. [Note; there were no Auxiliary water channels (L3) on the endoscopes used for simulated-use testing.]
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recommended that sites continue performing manual
cleaning until clinical-use data was published. Indeed this
concern was reiterated in 2009 by SGNA [23] where they
stated: "It is necessary to follow all steps for the manual
cleaning of the endoscope prior to using an automated
reprocessor. No independent confirmatory data are
currently available to show that automated reproces-
sors are able to provide cleaning of endoscopes that is
comparable to that of manual washing and brushing."
The results of our study are the first published data to
address this issue. Our clinical use study and simulated-
use study clearly demonstrated that the cleaning process
used by the ECR provided excellent removal of both
organic material (protein and hemoglobin) and biobur-
den from all flexible endoscopes evaluated. The clinical
study by Alfa et al [27] indicated that after complete man-
ual cleaning (before HLD) the range of residual material
in the suction/biopsy channels of Olympus broncho-
scopes, duodenoscopes and colonoscopes was 0 μg/cm2
to 4.40 μg/cm2 for hemoglobin, 3.51 to 8.55 μg/cm2 for
protein and 2.17 to 4.05 Log10/cm2  for bioburden.
Although the endoscope reprocessing staff in the clinic at
the time the 1999 study [27] was conducted were follow-
ing the Olympus flexible endoscope manufacturer's
cleaning instructions they were likely not adhering to it
completely as the average time required in the endoscopy
clinic for cleaning flexible endoscopes ranged from 5
minutes to 6.5 minutes [27] whereas research personnel
who timed all stages took between 14 minutes to 25 min-
utes to clean the same scope types. At the time of the
1999 [27] study, the endoscopy clinic cleaning protocol
was totally manual with no flushing pumps being used.
For simulated-use testing the residuals reported by Alfa
et al [22] for optimal manual cleaning by research person-
nel were lower (maximum residual protein was 4.46 μg/
cm2 ) compared to the residuals (up to 8.55 μg/cm2 ) left
after routine manual cleaning of patient-used flexible
endoscopes in a busy endoscopy clinic [27]. The data
from the current study demonstrated that for patient-
used flexible endoscopes the residuals for protein, hemo-
globin and bioburden in the suction channel (L1) after
the ECR cleaning are substantially better (99.7% met all
benchmarks) compared to optimal manual cleaning.
Indeed it is clear from the data on manual cleaning of
patient-used flexible endoscopes presented by Alfa et al
[27] that after routine manual cleaning in an endoscopy
clinic there are scopes that may have > 6.4 μg/cm2 of pro-
tein, > 1.8 μg/cm2 of hemoglobin and > 4 Log10 cfu/cm2
bioburden remaining.
The volume of fluid to be flushed through channels that
is required by endoscope manufacturers for the detergent
and rinse stages of manual cleaning is large. Olympus rec-
ommends 90 mLs per suction-biopsy channel for colono-
scopes and according to Puszko [12] 150 mLs per channel
is recommended by the Australian endoscope reprocess-
ing guidelines. For manual cleaning this requires staff to
use syringes filled with fluid and repeated manual flush-
ing that often leads to repetitive strain injuries [12]. The
use of stand alone pumps to facilitate the flushing of
cleaning and rinsing fluid has become widely accepted in
centres that can afford these pumps [12]. The use of
endoscope reprocessors with validated cleaning cycles
would greatly reduce the strain on staff and would stan-
dardize the fluid volume being flushed.
Despite the overall low rates of infection associated
with flexible endoscopy procedures, flexible endoscopes
are still the most common cause of healthcare device
associated out breaks [29]. Bisset et al [4] have showed
that the incidence of residual microbial contamination
for patient ready gastroscopes and duodenoscopes was
1.9% and 1.8% respectively. Furthermore, they indicated
that the incidence of bioburden contamination increased
with the number of times the endoscope was used. This
suggests that biofilm may form over repeated uses and
this may be related to the wide variation in the manual
cleaning performed [6,4]. The recent study by Alfa and
Howie [30] modelling build-up biofilm as well as the one
by Vickery et al [31] using endoscope tubing both con-
firm that repeated rounds of exposure to organic mate-
rial, cleaning and HLD (complete reprocessing) result in
an accumulation of material within the channel. The rate
of accumulation is modulated by organic load [30] and
type of detergent used [17]. The review by Moses and Lee
[6] reveal that only 70% of centers surveyed flushed
detergent through channels and used brushes for the
channels and valves (30% omitted manual cleaning and
relied on the AER to perform cleaning even though there
were no AERs at that time with FDA clearance for clean-
ing cycles). Marion et al [32] suggest that periodic use of
biofilm detaching agent may be needed to reduce the risk
of biofilm accumulation in scope channels. These studies
all suggest that in healthcare there is widespread diffi-
culty in achieving the endoscope manufacturers recom-
mended manual cleaning and that great variability exists
in the manual cleaning currently being performed.
The value of AERs with validated cleaning combined
with efficient HLD and final rinsing cannot be overem-
phasized. However, not all AER cleaning cycles are equiv-
alent as many of the "cleaning" cycles in commercially
available AERs do not have FDA cleared cleaning claims
and therefore still require manual cleaning prior to pro-
cessing in the AER. As indicated by Alfa and Howie [30]
when an aldehyde is used for HLD (as is the case for ECR)
it becomes critical that the cleaning needs to be thorough
and reproducible to reduce the risk of microbial survival
in accumulated organic material. Our data suggest thatAlfa et al. BMC Infectious Diseases 2010, 10:200
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because of the efficacy of the ECR cleaning cycle and the
fact that the cycle cannot be "shortened" by the user, the
potential for build-up biofilm would likely be reduced
compared to manual cleaning where short-cuts in clean-
ing are common.
The cleaning efficiencies achieved by the AdaptaScope
and LS 2000 AERs tested by Kircheis and Martiny [33]
using endoscope channel tubing indicated that efficient
microbial removal was only achieved when direct chan-
nel connection was used. The two "pressure chamber"
models of AERs evaluated could not achieve flow through
of the inoculated tubing therefore there was no biobur-
den reduction. The ECR evaluated in the current study
uses direct channel connection and the data from our
simulated-use study demonstrated that the RF achieved
by the cleaning cycle alone was > 6 for all surface sites and
> 4.5 for all air/water, suction/biopsy and auxillary water
channels for all types of flexible endoscopes. This further
extends Kircheis and Martiny's [33] work on tubing seg-
ments to demonstrate how efficient cleaning can be
achieved in the various channels and surface of flexible
endoscopes. The ECR was also able to achieve an entero-
coccus RF of > 4 for the elevator guidewire channel which
presents unique challenges to cleaning which were not
addressed in Kircheis and Martiny's [33] study. Indeed
this RF of 4.01 achieved by the ECR cleaning cycle is
superior to a previous report [22] for the Reliance AER
(RF of 2.10) cleaning as well as for complete manual
cleaning (RF of 3.22). The cleaning efficacy achieved
using an AER with "boot pressure chamber" technology
versus "direct channel connection" technology will
depend entirely on the manufacturer's specifications for
that particular machine. Both technologies have advan-
tages and disadvantages. Direct channel connection
allows for monitoring of individual channel flow
(although not all AERs with channel connections provide
this option) whereas this is not currently available for
"boot pressure chambers". Boot pressure chamber over-
comes possible user errors with channel connection mix-
ups that may occur with traditional AERs that use direct
channel connections. Users need to determine which
AER process best suites their needs and should thor-
oughly assess the validation data provided for any AER
they are considering.
It should be noted that it is difficult to assess the effects
of lumen anomalies such as scratches or biofilm buildup
on the efficacy of either manual or ECR cleaning. How-
ever, the in-use study using patient-used endoscopes does
p r o v i d e  v a l u a b l e  d a t a  o n  c l e a n i n g  e f f i c a c y  f o r  d e v i c e s
known to have been exposed to normal wear and tear
within the clinical setting.
Although only Olympus flexible endoscopes were
included in the current study, the data from this study
provides "proof of concept" that the cleaning technology
of the ECR is adequate. In the study by Alfa et al [22]
where Olympus, Pentax and Fujinon endoscopes were
evaluated [22] the AER cleaning cycle showed similar
cleaning efficiencies regardless of which manufacturer's
endoscopes were tested. In addition, as the ECR manu-
facturer completes validation of different scope types and
models they will be added to their list of validated endo-
scopes that can be processed through the ECR.
Conclusions
In summary the data presented for the simulated-use
testing and clinical use testing clearly demonstrate that
the cleaning cycle does provide reliable organic and
bioburden removal from 98.8% of surfaces and 99.7% of
lumens for the bronchoscopes, duodenoscopes, gastro-
scopes and colonoscopes that were tested. The ECR
cleaning for endoscope surfaces and channels is superior
to optimal manual cleaning providing all the ECR manu-
facturer's specific instructions are followed (including the
type of enzymatic detergent used in the ECR). Although
only Olympus flexible endoscopes were evaluated in this
study it does provide stringent proof of concept for the
cleaning phase of the ECR complete reprocessing cycle
(cleaning and HLD). This cleaning efficiency for patient-
used endoscopes is only validated for elective procedures
(not emergency endoscopies) and only if the bedside pre-
cleaning is done and the transit time is less than an hour
prior to placing the endoscope into the ECR.
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